CEP290 and respiratory distress syndrome in premature infants: Several approaches of gene therapies for IRDs exist, using Adeno-associated viral vectors (AAVs) or Lentivirus-mediated gene augmentation (providing normal cDNA, ex RPE65), and gene editing (CRISPR to knockout point mutation in deep intronic regions, e.g., CEP290 causing LCA110).